Geron Bails Out of Stem Cells - ScienceInsider: Stephen Kelsey, Geron's chief medical officer, said that so far patients showed neither significant side effects nor any improvement in their condition. Given the small scale of the study, he said, stopping early may not be such a loss. "We applied for and received permission to run a very small safety study with a low dose of cells," he said. "We're halfway through, and the data have been remarkably consistent. We will be reporting the results, and it will be a fair reflection of what would have happened if we had completed the study."
Related: Five Dumbest Things on Wall Street This Week (see page 3)
'via Blog this'
No comments:
Post a Comment